<DOC>
	<DOCNO>NCT00988884</DOCNO>
	<brief_summary>This study evaluate tolerability immunogenicity administration first dose V503 time Menactra™ Adacel™ versus administration V503 one month prior administration Menactra™ Adacel™ .</brief_summary>
	<brief_title>A Study V503 Given Concomitantly With Menactra™ Adacel™ 11 15 Year Olds ( V503-005 )</brief_title>
	<detailed_description />
	<mesh_term>Papillomavirus Infections</mesh_term>
	<criteria>Subject good health Subject 's parent/legal guardian read , understand , complete vaccine report card Subject sexually active plan become sexually active study Subject receive documented full primary immunization series diphtheria , tetanus , pertussis ( last 5 year ) Subject know allergy vaccine component V503 , Menactra™ , Adacel™ Subject condition contraindication vaccination Menactra™ Adacel™ Subject coagulation disorder Female subject pregnant Subject immunocompromised immunodeficient Subject splenectomy Subject receive immunosuppressive therapy prior year Subject receive immune globulin product bloodderived product last 3 month Subject receive inactivated vaccine within 14 day live vaccine within 21 day first study vaccination Subject receive marketed HPV vaccine participation HPV vaccine trial Subject receive meningococcal vaccine Subject fever &gt; = 100F within 24 hour vaccination Subject history HPV</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>